- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04460820
A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection
A Randomized,Open-label, Single-Dose,Two-Cycle,Crossover Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection Under Advanced Breast Cancers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050000
- Fourth Hospital of Hebei Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1.Voluntary agreement to provide written informed consent. 2.Patients with locally advanced or metastatic breast cancer diagnosed by histology or cytology,and who may benefit from monotherapy of Doxorubicin liposomes.
3.Females age 18 to 75 years, inclusive. 4.Body weight ≥45.0 kg, and BSA<1.80m2. 5.The ECOG performance status is 0 to 2. 6.The expected survival time is more than 3 months. 7.Subjects must have laboratory values within the limits described below: ANC ≥1.5 x 109/L PLT ≥100 x 109/L HB ≥90 g/L PT/INR and APTT ≤1.5 x ULN Cr ≤1.5 x ULN Serum total bilirubin ≤1.5 x ULN(OR ≤3 X ULN for subjects with liver metastases) AST (SGOT) and ALT (SGPT) ≤2.5 x ULN (OR ≤5 X ULN for subjects with liver metastases) 8.The subjects had no pregnancy plan and volunteered to use effective contraception and had no egg donation plan within 6 months after entering the study.
9.The subject will be able to communicate well with the investigator and understand and comply with the requirements of the study.
Exclusion Criteria:
1.Significant allergy, hypersensitivity or idiosyncratic reactions to doxorubicin and/or any related compounds.
2.Treatments were terminated due to treatment failure or serious adverse reactions in subjects who had previously used doxorubicin liposomes.
3.Patients with severe cardiovascular, lung, liver, kidney, gastrointestinal, endocrine, immune system, skin, musculoskeletal, neurological or psychiatric conditions that the researchers did not consider appropriate for inclusion.
4.Patients who had undergone major surgery within 3 months before screening, or planned to undergo major surgery during the study period.
5.Having a history of alcoholism, drug abuse or drug abuse. 6.The results of alcohol breath test were more than 0.0mg/100ml or drug abuse screening was positive (Methamphetamine, ketamine, MDMA,Tetrahydrocannabinol).
7.Pregnant or breast-feeding female. 8.Positive result to any of the following: HIV-1/2, hepatitis B and C; syphilis.
9.Study drug prior to radiation or the use of chemotherapy drugs less than 28 days, or other antineoplastic therapy (e.g., endocrine therapy, Chinese medicine treatment, the local radiotherapy of pain relief, etc.) is less than 14 days, or during the study period need to merge the other anti-tumor drug treatment.
10.Impaired cardiac function: QTc>470ms; LVEF(left ventricular ejection fraction) below 50% or below institutional normal at screening; Congestive heart failure of grade≥ 2 from NYHA classification, myocardial infarction or uncontrolled angina pectoris occurred within 6 months before enrollment; Have had bypass surgery; 11. Blood donation or massive blood loss within 90 days before screening (> 400ml) .
12.The total cumulative dose of doxorubicin was ≥300mg/m2 before screening, or previous administration of anthracycline caused severe cardiotoxicity.
13.Eating a specific diet (such as grapefruit) within 48 hours prior to enrollment can affect drug absorption, distribution, metabolism, and excretion.
14.Participating in other clinical trials and accepting clinical trial drugs within 28 days prior to enrollment.
15.Other researchers judged unsuitable for participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Doxorubicin Hydrochloride Liposome Injection
50mg/m2 ,IV on Day 1 of each cycle
|
50mg/m2,IV on Day 1 of each cycle
|
Active Comparator: Doxorubicin Hydrochloride Liposome Injection(Caelyx®)
50mg/m2 ,IV on Day 1 of each cycle
|
50mg/m2,IV on Day 1 of each cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: up to 15 days post-adminstration
|
The pharmacokinetics(PK) profile of Doxorubicin Hydrochloride Liposome Injection
|
up to 15 days post-adminstration
|
AUC
Time Frame: up to 15 days post-adminstration
|
The pharmacokinetics(PK) profile of Doxorubicin Hydrochloride Liposome Injection
|
up to 15 days post-adminstration
|
Tmax
Time Frame: up to 15 days post-adminstration
|
The pharmacokinetics(PK) profile of Doxorubicin Hydrochloride Liposome Injection
|
up to 15 days post-adminstration
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DRBX201901/PRO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bioequivalence
-
Pharmtechnology LLCRecruitingBioequivalenceRussian Federation
-
Emzor Pharmaceutical Industries LimitedNot yet recruiting
-
Pharmtechnology LLCClinPharmInvest, LLCNot yet recruitingBioequivalenceRussian Federation
-
Indiana UniversityFood and Drug Administration (FDA)Completed
-
AstraZenecaCompletedBioequivalenceUnited States
-
Future University in EgyptCompleted
-
Cross Research S.A.Zambon SpACompleted
-
Laboratorios Andromaco S.A.Completed
-
Emzor Pharmaceutical Industries LimitedUnknown
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
Clinical Trials on Doxorubicin Hydrochloride Liposome Injection
-
InxMed (Shanghai) Co., Ltd.Active, not recruitingLocally Advanced or Metastatic Solid TumorsChina
-
Ayana Pharma Ltd.,Lambda Therapeutic Research Ltd.CompletedOvarian Cancer RecurrentIndia
-
Fudan UniversityRecruitingAdvanced Malignant TumorsChina
-
Luye Pharma Group Ltd.CompletedAdvanced Breast CancerChina
-
Dr. Reddy's Laboratories LimitedCompletedOvarian Epithelial Cancer RecurrentIndia
-
TelikCompletedOvarian NeoplasmsUnited States, Czech Republic, South Africa, Argentina, Belgium, Spain, Brazil, Chile, Germany, Hungary, Ireland, Netherlands, United Kingdom
-
Tianjin Medical University Second HospitalCSPC Pharmaceutical Group LimitedUnknownMuscle Invasive Bladder CancerChina
-
Baxter Healthcare CorporationNot yet recruitingMultiple Myeloma | Ovarian Cancer | Metastatic Breast Cancer | AIDS-related Kaposi Sarcoma
-
Shenzhen Kangzhe Pharmaceutical Co., Ltd.Hunan Cancer Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University and other collaboratorsRecruitingBreast Cancer | Ovarian CancerChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingFallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer